Boston Scientific has introduced Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent System in China.

The Promus Coronary Stent System is the company’s third-generation drug-eluting stent (DES) technology which includes a platinum chromium (PtCr) alloy, stent design and advanced catheter delivery system.

The stent provides greater strength, increased deliverability and visibility, and is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution.

Boston Scientific senior vice president and president Larry Neumann said the Chinese government has announced its intention to spend $125 billion on its healthcare system in the next five years.

"We are making significant investments in our sales, distribution and clinical infrastructure in China and this important launch reflects our goal to win global market share as part of our Power strategic plan." Neumann said.

The company’s Board of Directors have granted a five-year,$150m investment in China to built a local, wholly owned manufacturing facility in order to serve Chinese market needs and develop a training center for Chinese healthcare providers.